Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-05
2005-04-05
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S256000, C514S269000
Reexamination Certificate
active
06875773
ABSTRACT:
The present invention pertains to methods for therapeutic and prophylactic treatment of cats against FIV infection. Methods of the present invention utilize a combination of antiretroviral compounds to treat or prevent FIV infection in a feline animal. In one embodiment, the method comprises administering an effective amount of AZT and another nucleoside analog, such as, for example, 3TC to the animal. In another embodiment, cats are given an effective dose(s) of AZT, 3TC, and a retroviral protease inhibitor.
REFERENCES:
patent: 197 03 131 (1998-07-01), None
patent: WO 9622778 (1996-08-01), None
patent: WO 9623509 (1996-08-01), None
patent: WO 9630025 (1996-10-01), None
patent: WO 9703055 (1997-01-01), None
patent: WO 9749411 (1997-12-01), None
patent: WO 9955372 (1999-11-01), None
patent: WO 9966936 (1999-12-01), None
Goodman & Gilman's, The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw-Hill, New York, (1996), Chapter 50, p. 1192.*
CAPLUS, DN 123:102047, Budt et al., Bioorganic & Medicinal Chemistry (1995), 3(5), 559-71 (abstract only).*
Boucher, C. A. B. et al. “High-Level Resistance to (−) Enantiomeric 2′-Deoxy -3′—Thiacytidine In Vitro Is Due to One Amino Acid Substitution in the Catalytic Site of Human Immunodeficiency Virus Type 1 Reverse Transcriptase”Antimicrobial Agents And Chemotherapy,Oct. 1993, pp. 2231-2234, vol. 37, No. 10.
Deeks, S. G. et al. “HIV-1 Protease Inhibitors”JAMA,Jan. 8, 1997, pp. 145-153, vol. 277, No. 2.
Dunn, B. M. et al. “Subsite Preferences of Retroviral Proteinases”Methods in Enzymology,1994, pp. 254-278, vol. 241, Academic Press, Inc.
Gardner, M. B. “Simian and Feline Immunodeficiency Viruses: Animal Lentivirus Models for Evaluation of AIDS Vaccines and Antiviral Agents”Antiviral Research,1991, pp. 267-286, vol. 15, Elsevier Science Publishers B.V.
Harrigan, R. “Measuring Viral Load in the Clinical Setting”Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology,1995, pp. S34-S40, vol. 10 (Suppl. 1), Lippincott-Raven Publishers, Philadelphia.
Hart, S. et al. “Long-Term Treatment of Diseased, FIV-Seropositive Field Cats with Azidothymidine (AZT)”J. Vet. Med. A.,1995, pp. 397-409, vol. 42, Blackwell Wissenschafts, Verlag, Berlin.
Hartmann, K. et al. “Use of Two Virustatica (AZT, PMEA) in the Treatment of FIV and of FeLV Seropositive Cats with Clinical Symptoms”Veterinary Immunology and Immunopathology,1992, pp. 167-175, vol. 35, Elsevier Science Publishers B.V., Amsterdam.
Hayes, K. A. et al. “Prophylactic ZDV Therapy Prevents Early Viremia and Lymphocyte Decline But Not Primary Infection In Feline Immunodeficiency Virus-Inoculated Cats”Journal of Acquired Immune Deficiency Syndromes,1993, pp. 127-134, vol. 6, Raven Press, Ltd., New York.
Hayes, K. A. et al. “Early Suppression of Viremia by ZDV Does Not Alter the Spread of Feline Immunodeficiency Virus Infection in Cats”Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology,1995, pp. 114-122, vol. 9, No. 2, Raven Press. Ltd., New York.
Johnson, C. M. et al. “FIV as a Model for AIDS Vaccination”AIDS Research and Human Retroviruses,1994, pp. 225-228, vol. 10, No. 3, Mary Ann Liebert, Inc., Publishers.
Katlama, C. “Combination 3TC (Lamivudine)/ ZDV (Zidovudine) Vs. ZVD Monotherapy in ZVD Naive HIV-1 Positive Patients With CD4 of 100-400 Cells/mm3, Abstr”AIDS,1994, p. 56, vol. 8 (Suppl. 4).
Lange, J. M. A. “Triple Combinations: Present and Future”Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology,1995, pp. S77-S82, vol. 10 (Supp. 1), Lippincott-Raven Publishers, Philadelphia.
Larder, B. A. “Viral Resistance and the Selection of Antiretroviral Combinations”Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology,1995, pp. S28-S33, vol. 10 (Suppl. 1), Lippincott-Raven Publishers, Philadelphia.
Magnani, M. et al. “Feline Immunodeficiency Virus Infection of Macrophages: In Vitro and in Vivo Inhibition by Dideoxycytidine-5′-triphosphate-Loaded Erythrocytes”AIDS Research and Human Retroviruses,1994, pp. 1179-1186, vol. 10, No. 9, Mary Ann Liebert, Inc., Publishers.
Meers, J. et al. “Feline Immunodeficiency Virus Infection: Plasma, but not Peripheral Blood Mononuclear Cell Virus Titer is Influenced by Zidovudine and Cyclosporine”Arch Virol,1993, pp. 67-81, vol. 132.
Newell, M. L. et al. “A Risk-Benefit Assessment of Zidovudine in the Prevention of Perinatal HIV Transmission”Drug Safety,1995, pp. 274-281, vol. 12, No. 4.
North, T. W. et al. “Feline Immunodeficiency Virus, a Model for Reverse Transcriptase-Targeted Chemotherapy for Acquired Immune Deficiency Syndrome”Antimicrobial Agents and Chemotherapy,Jun. 1989, pp. 915-919, vol. 33, No. 6, American Society for Microbiology.
Paul, D. B. et al. “Short-Term Stability of HIV Provirus Levels in the Peripheral Blood of HIV-Infected Individuals”Journal of Medicinal Virology,1995, pp. 292-297, vol. 47, Wiley-Liss, Inc.
Pedersen, N. C. et al. “Isolation of a T-Lymphotropic Virus from Domestic Cats with an Immunodeficiency-Like Syndrome”Science,1987, pp. 790-793, vol. 235.
Philpott, M. S. et al. “Evaluation of 9-(2-Phosphonylmethoxyethyl) Adenine Therapy for Feline Immunodeficiency Virus Using a Quantitative Polymerase Chain Reaction”Veterinary Immunology and Immunopathology,1992, p. 155-166, vol. 35, Elsevier Science Publishers B. V., Amsterdam.
Siebelink, K. H.J. et al. “Feline Immunodeficiency Virus (FIV) Infection in the Cat as a Model for HIV Infection in Man: FIV-Induced Impairment of Immune Function”AIDS Research and Human Retroviruses,1990, pp. 1373-1378, vol. 6, No. 12, Mary Ann Liebert, Inc., Publishers.
Smith, R. A. et al. “A Novel Point Mutation at Position 156 of Reverse Transcriptase from Feline Immunodeficiency Virus Confers Resistance to the Combination of (−)-β2′,3′-Dideoxy-3′-Thiacytidine and 3′-Azido-3′-Deoxythymidine”Journal of Virology,1998, pp. 2335-2340, vol. 72, No. 3.
Smith, R. A. et al. “A Novel Met-to-Thr Mutation in the YMDD Motif of Reverse Transcriptase from Feline Immunodeficiency Virus Confers Resistance to Oxathiolane Nucleosides”Journal of Virology,1997, pp. 2357-2362, vol. 71, No. 3.
Smyth,N. R. et al. “Susceptibility in Cell Culture of Feline Immunodeficiency Virus to Eighteen Antiviral Agents”Journal of Antimicrobial Chemotherapy,1994, pp. 589-594, vol. 34.
Smyth, N. R. et al. “Effect of 3′Azido-2′,3′-Deoxythymidine (AZT) on Experimental Feline Immunodeficiency Virus Infection in Domestic Cats”Research in Veterinary Science,1994, pp. 220-224, vol. 57.
Tisdale, M. et al. “Rapid in Vitro Selection of Human Immunodeficiency Virus Type 1 Resistant to 3′-Thiacytidine Inhibitors Due to a Mutation in the YMDD Region of Reverse Transcriptase”Proc. Natl. Acad. Sci. USA,Jun. 1993, pp. 5653-5656, vol. 90.
Torres, R. A. et al. “Combination Antiretroviral Therapy for HIV Infection”Infect. Med.,Feb. 1997, pp. 142-160, vol. 14.
Wlodawer, A. et al. “Structure of an Inhibitor Complex of the Proteinase From Feline Immunodeficiency Virus”Nature Structural Biology,Jun. 1995, pp. 480-488, vol. 2, No. 6.
Yamamoto, J. et al. “Pathogenesis of Experimentally Induced Feline Immunodeficiency Virus Infection in Cats”Am J Vet Res,Aug. 1988, pp. 1246-1258, vol. 49, No. 8.
Yamamoto, J. et al. “Feline Immunodeficiency Syndrome—A Comparison Between Feline T-Lymphotropic Lentivirus and Feline Leukemia Virus”Leukemia,Dec. 1988, pp. 204S-215S, vol. 2, No. 12 Supplement.
Arai Maki
Dunn Ben M.
Yamamoto Janet K.
Delacroix-Muirheid C.
Low Christopher S. F.
Saliwanchik Lloyd & Saliwanchik
LandOfFree
Combination therapy for treatment of FIV infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy for treatment of FIV infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for treatment of FIV infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3378380